Anika Therapeutics, Inc. (ANIK)
- Sector
- Biotechnology
- Last price
- $21.55
- As of
Kresmion compiles this page from ANIK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Anika Therapeutics, Inc. (ANIK): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-29.
See the full ANIK dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ANIK on one page. Preview it with sample data, then open it live with a free account.
Preview the ANIK dossierActive events for ANIK
- mediumEarnings above estimates
Q1-2026: Beat consensus by 265.4%, EPS $0.27 vs $-0.1632 estimate
- mediumEarnings above estimates
Q2-2026: Beat consensus by 614.7%, EPS $0.42 vs $-0.0816 estimate
FREE, NO ACCOUNT
Every event on ANIK, as it fires
New filings, 13F moves and cross asset events on ANIK land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ANIK (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 035255108 · 2026Q2 | $7M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 035255108 · 2026Q2 | $3.7M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 035255108 · 2026Q2 | $3.6M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 035255108 · 2026Q2 | $329K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 035255108 · 2026Q2 | $211K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ANIK
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ANIK against its peers
ANIK's operating margin of -9.8% ranks in the 83rd percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ANIK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 113M USD | 12.1M USD | 86 | 17 |
| Gross margin | 56.6% | n/a | n/a | 3 |
| Operating margin | -9.8% | -261.7% | 83 | 14 |
| Net margin | -9.6% | -287.4% | 63 | 14 |
| Return on equity | -7.6% | -42.5% | 69 | 17 |
Peers (22): AGEN, IRD, PRLD, PROK, ARCT, SRZN, ARTV, BNTC, IPSC, CTNM, TTRX, SABS, EBS, NWBO, XFOR, GALT, ZURA, LCTX, FATE, ABEO, QTTB, RCKT. Left out: VOGX (no annual filing), CUVL (no annual filing), VCRE (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ANIK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ANIK on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ANIK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.